Study ID | Age mean ± SD [Range], y | Gender (F/M) | Intervention | Standard treatments | Compliance (%) | FEV1% | Run in period | Treatment duration | Type of intervention | Reported outcomes | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|
 |  |  |  |  |  |  |  |  |  | AE | AES | AEE |
Boushey HA 2005 [8] | T: 33.6 ± 11.1 | T: 47/29 | T: Z 20 mg + IP bid | IB 800 ug bid × 10D or prednisone × 5D if asthma worsened | > 90 | ≥ 70 | 4 weeks | 48 weeks | First-line/add-on | + | — | + |
C1: 33.2 ± 9.5 | C1: 48/25 | C1: IB 200 ug + OP bid | ||||||||||
C2: 32.0 ± 10.5 | C2: 43/33 | C2: IP + OP bid | ||||||||||
Huang CJ 2003 [9] | T: 58.6 ± 3.0 | T: 8/9 | T: Z 20 mg bid | IB (≥ 400 μg/day or equivalent) + SABA | NR | Moderate | 2 weeks | 4 weeks | Add-on | + | — | + |
C: 56.9 ± 2.8 | C: 7/7 | C: Placebo 20 mg bid | ||||||||||
Brabson JH 2002 [10] | T: 35 ± 16 | T: 141/75 | T: Z 20 mg bid | Albuterol as needed | ≥ 88 | 60-85 | 8 days | 6 weeks | First-line | + | + | + |
C: 36 ± 14 | C: 134/90 | C: IFP 88 ug bid | ||||||||||
Nathan RA 2001 [11] | T: 32 | T: 65/85 | T: Z 20 mg bid | Albuterol as needed | NR | 50-80 | 7-14 days | 4 weeks | First-line | + | — | — |
C: 31 | C: 79/65 | C: Fluticasone 88 ug bid | ||||||||||
Busse W 2001 [12] | T: 12-75 | T: NR | T: Z 20 mg + IP bid | Albuterol as needed, or oral or parental corticosteriods for AE | NR | 50-80 | 8-14 days | 12 weeks | First-line/add-on | + | + | — |
C: 12-75 | C: NR | C1: IFP 88 ug + OP bid | ||||||||||
 |  | C2: IP + OP bid | ||||||||||
Kim KT 2000 [13] | T: 32.9 | T: 127/89 | T: Z 20 mg + IP bid | Albuterol as needed | 88 | 60- 85 | 1 week | 6 weeks | First-line | + | + | + |
C: 35.5 | C: 135/86 | C: IFP 88 ug bid | ||||||||||
Virchow JCJr 2000 [14] | T: 47.4 ± 12.6 | T: 85/95 | T: Z 80 mg bid | Beclomethasone ≥ 1200 ug/day or equivalent) + SABA | T: 95 | 50-75 | 2 weeks | 6 weeks | Add-on | + | — | — |
C: 49.2 ± 12.9 | C: 98/90 | C: Placebo 80 mg bid | C: 94 | |||||||||
Bleecker ER 2000 [15] | T: 31 | T: 113/107 | T: Z 20 mg bid | Albuterol as needed | 92 | 50-80 | 8-14 days | 12 weeks | First-line | + | — | — |
C: 31 | C: 112/119 | C: IFP 88 ug bid | ||||||||||
Busse W 1999 [16] | T: 36.9 | T: 85/60 | T: Z 20 mg bid | Albuterol as needed | NR | 50-80 | 7-14 days | 4 week | First-line | + | — | — |
C: 38.6 | C: 77/67 | C: SX 42 ug bid | ||||||||||
Nathan RA 1998 [17] | T: 33.2 | T: 127/104 | T: Z 20 mg bid | SABA as needed | NR | 45-80 | 2-3 weeks | 13 weeks | First-line | + | + | — |
C: 32.1 | C: 132/91 | C: Placebo 20Â mg bid | ||||||||||
Fish JE 1997 [18] | T: > 12 | T: 220/294 | T: Z 20 mg bid | Albuterol as needed | NR | > 55 | 7-14 days | 13 weeks | First-line | + | — | — |
C: > 12 | C: 102/146 | C: Placebo 20 mg bid | ||||||||||
Spector SL 1994 [19] | T: Z1: 37, Z2: 35, Z3: 36, C: 36 | T: Z1: 18/52, Z2: 23/45, Z3: 18/50, C: 20/50 | T: Z1: 20 mg bid, Z2: 10 mg bid, Z3: 5 mg bid, C: Placebo bid | Albuterol as needed | NR | 40-75 | 2 weeks | 6 weeks | First-line | + | — | — |